Last reviewed · How we verify
treatment of mild to moderate covid 19
Approved treatments
Clinical guidelines
- FDA label — 1L
PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- treatment of mild to moderate covid 19 patent landscape — cliff calendar, originator estates, attackable patents
- treatment of mild to moderate covid 19 treatment landscape brief
- treatment of mild to moderate covid 19 treatment updates RSS
Frequently asked questions about treatment of mild to moderate covid 19
What are the treatment guidelines for treatment of mild to moderate covid 19?
FDA label publishes guidelines for treatment of mild to moderate covid 19. 1 guideline references tracked.
Related
- Treatment landscape: treatment of mild to moderate covid 19 patent cliff · treatment of mild to moderate covid 19 CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing